分析帕德斯生物科学（PRDS）及其竞争对手

Pardes Biosciences (NASDAQ:PRDS – Get Rating) is one of 992 public companies in the "Pharmaceutical preparations" industry, but how does it weigh in compared to its competitors? We will compare Pardes Biosciences to similar companies based on the strength of its analyst recommendations, institutional ownership, dividends, earnings, valuation, profitability and risk.

Insider & Institutional Ownership

40.6% of shares of all "Pharmaceutical preparations" companies are held by institutional investors. 45.1% of Pardes Biosciences shares are held by company insiders. Comparatively, 15.7% of shares of all "Pharmaceutical preparations" companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Pardes Biosciences and its competitors' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and price targets for Pardes Biosciences and its competitors, as reported by MarketBeat.com.

Pardes Biosciences presently has a consensus price target of $3.50, suggesting a potential upside of 110.84%. As a group, "Pharmaceutical preparations" companies have a potential upside of 112.69%. Given Pardes Biosciences' competitors stronger consensus rating and higher probable upside, analysts clearly believe Pardes Biosciences has less favorable growth aspects than its competitors.

Volatility and Risk

Pardes Biosciences has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500. Comparatively, Pardes Biosciences' competitors have a beta of 0.90, indicating that their average stock price is 10% less volatile than the S&P 500.

Valuation and Earnings

This table compares Pardes Biosciences and its competitors top-line revenue, earnings per share (EPS) and valuation.

Pardes Biosciences' competitors have higher revenue and earnings than Pardes Biosciences. Pardes Biosciences is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Pardes Biosciences competitors beat Pardes Biosciences on 9 of the 13 factors compared.

About Pardes Biosciences

(Get Rating)

Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.

Receive News & Ratings for Pardes Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pardes Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.